GHB Prodrug Derivatives for Narcolepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Sodium oxybate, used to treat narcolepsy and related symptoms, has sub-optimal pharmacokinetics leading to variable bioavailability, unpredictable plasma concentrations, and inconvenient administration, limiting its therapeutic effectiveness.
Innovation Solution
Development of novel compounds with specific chemical structures, such as those represented by Formula I, which are designed to improve bioavailability, stability, and dosing regimen, including the use of pharmaceutically acceptable salts, esters, hydrates, or solvates, to enhance therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sodium oxybate is administered to treat narcolepsy, then cataplexy episodes are reduced by approximately 70%, but oral bioavailability is variable and plasma concentrations are unpredictable
Solution Approach 1:
The patent modifies the chemical parameters of GHB by creating prodrug derivatives with different molecular structures (Formula I compounds). These structural changes alter pharmacokinetic parameters including absorption rate, bioavailability, and plasma concentration profiles, thereby achieving more predictable and reliable therapeutic levels while maintaining efficacy.
Solution Approach 2:
The patent introduces prodrug intermediaries that convert to active GHB in the body. These intermediary compounds facilitate improved absorption and delivery of the active principle, acting as carriers that enhance bioavailability and reduce the variability in plasma concentrations associated with direct GHB administration.
2Reliability
If sodium oxybate is administered to treat narcolepsy, then cataplexy and excessive daytime sleepiness are treated effectively, but administration is inconvenient and compliance is poor
Solution Approach 1:
The patent creates dynamic dosing formulations with sustained-release properties that adapt to the patient's needs over time. The modified compounds provide prolonged therapeutic effects, allowing for less frequent dosing and more flexible administration schedules, thereby improving convenience and compliance while maintaining effective treatment.
Solution Approach 2:
The patent employs periodic action through sustained-release formulations that deliver the drug at controlled intervals. This periodic delivery system maintains therapeutic levels over extended periods, reducing the frequency of administration required and improving patient convenience without compromising treatment efficacy.
3Reliability
If sodium oxybate is administered to treat narcolepsy, then therapeutic benefits are achieved, but side effects occur and dosing regimen is complex
Solution Approach 1:
The patent applies local quality by modifying specific regions of the GHB molecule to create derivatives with improved properties. By altering specific parts of the molecular structure (Formula I variations), the patent achieves selective improvement in pharmacokinetic profile and reduced side effects while preserving the core therapeutic activity of GHB.
Solution Approach 2:
The patent converts the harmful short half-life and rapid clearance of GHB into a benefit by designing prodrugs with extended circulation time and controlled release profiles. The very property that causes rapid elimination is transformed into sustained therapeutic presence through metabolic conversion of the prodrug intermediaries.
Data Source
AI summary
Provided are prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.